Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I; Withdrawal of Proposed Rule, 52712 [2022-18729]
Download as PDF
<![CDATA[
52712
Federal Register / Vol. 87, No. 166 / Monday, August 29, 2022 / Proposed Rules
V–433 [Amended]
From Bridgeport, CT; INT Bridgeport 324°
and Pawling, NY, 160° radials; Pawling; INT
Pawling 304° and Rockdale, NY, 116° radials;
Rockdale; INT Rockdale 325° and Syracuse,
NY, 100° radials; to Syracuse.
*
*
*
*
*
V–483 [Amended]
From Syracuse, NY; Rochester, NY; INT
Syracuse 283° and Rochester 064° radials;
Rochester.
*
*
*
*
*
*
*
V–499 [Removed]
*
*
*
Issued in Washington, DC, on August 23,
2022.
Scott M. Rosenbloom,
Manager, Airspace Rules and Regulations.
[FR Doc. 2022–18484 Filed 8–26–22; 8:45 am]
BILLING CODE 4910–13–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA824]
Schedules of Controlled Substances:
Placement of 2,5-dimethoxy-4iodoamphetamine (DOI) and 2,5dimethoxy-4-chloroamphetamine
(DOC) in Schedule I; Withdrawal of
Proposed Rule
Drug Enforcement
Administration, Department of Justice.
ACTION: Withdrawal of proposed rule.
AGENCY:
The Drug Enforcement
Administration (DEA) is withdrawing a
proposed rule that was published in the
Federal Register on April 11, 2022,
which proposed to place two
phenethylamine hallucinogens in
schedule I of the Controlled Substances
Act. DEA is withdrawing the proposed
rule, terminating all proceedings related
thereto, and will be publishing a new
proposed rule using an amended
procedure.
DATES: The proposed rule that was
published in the Federal Register on
April 11, 2022 (87 FR 21069), is
withdrawn as of August 25, 2022, and
all proceedings related thereto are
terminated.
FOR FURTHER INFORMATION CONTACT:
Terrence L. Boos, Ph.D., Chief, Drug and
Chemical Evaluation Section, Diversion
Control Division, Drug Enforcement
Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia
22152; Telephone: (571) 362–3249.
SUPPLEMENTARY INFORMATION: On April
11, 2022, the Drug Enforcement
khammond on DSKJM1Z7X2PROD with PROPOSALS
SUMMARY:
VerDate Sep<11>2014
16:15 Aug 26, 2022
Jkt 256001
Administration (DEA) published a
Notice of Proposed Rulemaking (NPRM)
in the Federal Register (87 FR 21069) to
place two phenethylamine
hallucinogens—specifically, 2,5dimethoxy-4-iodoamphetamine (DOI),
and 2,5-dimethoxy-4chloroamphetamine (DOC)—in schedule
I of the Controlled Substances Act (CSA)
(21 U.S.C. 801, et seq.).
DEA has determined that it is
appropriate to withdraw the proposed
rule published in the Federal Register
on April 11, 2022 (87 FR 21069), and to
terminate all proceedings related
thereto. DEA is planning to publish a
new proposed rule with an amended
procedure.
Signing Authority
This document of the Drug
Enforcement Administration was signed
on August 25, 2022, by Administrator
Anne Milgram. That document with the
original signature and date is
maintained by DEA. For administrative
purposes only, and in compliance with
requirements of the Office of the Federal
Register, the undersigned DEA Federal
Register Liaison Officer has been
authorized to sign and submit the
document in electronic format for
publication, as an official document of
DEA. This administrative process in no
way alters the legal effect of this
document upon publication in the
Federal Register.
Scott Brinks,
Federal Register Liaison Officer, Drug
Enforcement Administration.
[FR Doc. 2022–18729 Filed 8–26–22; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
42 CFR Part 493
[CMS–3326–N]
RIN 0938–AT47
Clinical Laboratory Improvement
Amendments of 1988 (CLIA) Fees;
Histocompatibility, Personnel, and
Alternative Sanctions for Certificate of
Waiver Laboratories; Extension of
Comment Period
Centers for Medicare &
Medicaid Services (CMS), HHS; Centers
for Disease Control and Prevention
(CDC), HHS.
ACTION: Proposed rule; extension of
comment period.
AGENCY:
PO 00000
Frm 00008
Fmt 4702
Sfmt 4702
The Centers for Medicare &
Medicaid Services (CMS) and the
Centers for Disease Control and
Prevention (CDC) within the
Department of Health and Human
Services (HHS) announce the extension
of the comment period for the proposed
rule entitled ‘‘Clinical Laboratory
Improvement Amendments of 1988
(CLIA) Fees; Histocompatibility,
Personnel, and Alternative Sanctions for
Certificate of Waiver Laboratories.’’
DATES: The comment period for the
proposed rule published July 26, 2022
(87 FR 44896), is extended through
September 26, 2022.
ADDRESSES: In commenting, please refer
to file code CMS–3326–P.
Comments, including mass comment
submissions, must be submitted in one
of the following three ways (please
choose only one of the ways listed):
1. Electronically. You may submit
electronic comments on this regulation
to https://www.regulations.gov. Follow
the ‘‘Submit a comment’’ instructions.
2. By regular mail. You may mail
written comments to the following
address ONLY: Centers for Medicare &
Medicaid Services, Department of
Health and Human Services, Attention:
CMS–3326–P, P.O. Box 8016, Baltimore,
MD 21244–8016.
Please allow sufficient time for mailed
comments to be received before the
close of the comment period.
3. By express or overnight mail. You
may send written comments to the
following address ONLY: Centers for
Medicare & Medicaid Services,
Department of Health and Human
Services, Attention: CMS–3326–P, Mail
Stop C4–26–05, 7500 Security
Boulevard, Baltimore, MD 21244–1850.
FOR FURTHER INFORMATION CONTACT:
Sarah Bennett, CMS, (410) 786–3531,
Serafina Brea, CMS, (410) 786–3531, or
Heather Stang, CDC, 404–498–2769.
SUPPLEMENTARY INFORMATION: In the
‘‘Clinical Laboratory Improvement
Amendments of 1988 (CLIA) Fees;
Histocompatibility, Personnel, and
Alternative Sanctions for Certificate of
Waiver Laboratories’’ proposed rule that
appeared in the July 26, 2022 Federal
Register (87 FR 44896), we solicited
public comments on proposed changes
to CLIA fees, histocompatibility and
personnel requirements, and alternative
sanctions for Certificate of Waiver
laboratories.
In response to requests we received
from several laboratory professional
organizations, we are extending the
comment period an additional 30 days.
This extension will maximize the
opportunity for the public to provide
SUMMARY:
E:\FR\FM\29AUP1.SGM
29AUP1
]]>Agencies
[Federal Register Volume 87, Number 166 (Monday, August 29, 2022)]
[Proposed Rules]
[Page 52712]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-18729]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA824]
Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-
iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in
Schedule I; Withdrawal of Proposed Rule
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Withdrawal of proposed rule.
-----------------------------------------------------------------------
SUMMARY: The Drug Enforcement Administration (DEA) is withdrawing a
proposed rule that was published in the Federal Register on April 11,
2022, which proposed to place two phenethylamine hallucinogens in
schedule I of the Controlled Substances Act. DEA is withdrawing the
proposed rule, terminating all proceedings related thereto, and will be
publishing a new proposed rule using an amended procedure.
DATES: The proposed rule that was published in the Federal Register on
April 11, 2022 (87 FR 21069), is withdrawn as of August 25, 2022, and
all proceedings related thereto are terminated.
FOR FURTHER INFORMATION CONTACT: Terrence L. Boos, Ph.D., Chief, Drug
and Chemical Evaluation Section, Diversion Control Division, Drug
Enforcement Administration; Mailing Address: 8701 Morrissette Drive,
Springfield, Virginia 22152; Telephone: (571) 362-3249.
SUPPLEMENTARY INFORMATION: On April 11, 2022, the Drug Enforcement
Administration (DEA) published a Notice of Proposed Rulemaking (NPRM)
in the Federal Register (87 FR 21069) to place two phenethylamine
hallucinogens--specifically, 2,5-dimethoxy-4-iodoamphetamine (DOI), and
2,5-dimethoxy-4-chloroamphetamine (DOC)--in schedule I of the
Controlled Substances Act (CSA) (21 U.S.C. 801, et seq.).
DEA has determined that it is appropriate to withdraw the proposed
rule published in the Federal Register on April 11, 2022 (87 FR 21069),
and to terminate all proceedings related thereto. DEA is planning to
publish a new proposed rule with an amended procedure.
Signing Authority
This document of the Drug Enforcement Administration was signed on
August 25, 2022, by Administrator Anne Milgram. That document with the
original signature and date is maintained by DEA. For administrative
purposes only, and in compliance with requirements of the Office of the
Federal Register, the undersigned DEA Federal Register Liaison Officer
has been authorized to sign and submit the document in electronic
format for publication, as an official document of DEA. This
administrative process in no way alters the legal effect of this
document upon publication in the Federal Register.
Scott Brinks,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2022-18729 Filed 8-26-22; 8:45 am]
BILLING CODE 4410-09-P
